Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis
Julia Clabbers, Celeste Boesjes, Lotte S. Spekhorst, Marike W. van Gisbergen, Emmy Maas, Josephine Marshall, Renske Janssen, Miranda Janssen, Nicolaas P. A. Zuithoff, Peter M. Steijlen, Marlies de Graaf, Michel van Geel, Marjolein de Bruin‐Weller, Antoni Gostyński
Abstract
BACKGROUND: Pathogenic variants in filaggrin (FLG) are associated with an increased risk of atopic dermatitis (AD). OBJECTIVE: We evaluated the influence of FLG variants on the effectiveness of dupilumab treatment in AD. METHODS: This prospective observational study included adult AD patients treated with dupilumab from the BioDay registry. FLG was analyzed with single-molecule molecular inversion probe-targeted sequencing. Novel mutations were confirmed by Sanger sequencing. Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), numeric rating scale (NRS) pruritus, Dermatology Quality of Life Index (DLQI), and Patient-Oriented Eczema Measure (POEM) were assessed at baseline and at weeks 16 and 52. The study was registered at ClinicalTrials.gov as NCT03549416. RESULTS: , while differences in delta scores were nonsignificant. CONCLUSION: The effectiveness of dupilumab treatment in AD patients was not influenced by pathogenic FLG variants. However, patients with biallelic pathogenic FLG variants tended to have drier skin before and during dupilumab treatment compared to patients with monoallelic pathogenic variants or wild-type alleles.